Back To Top

You have matched to 7 trials

Guest Profile:  Lobular

Copy link
Sort by zip code: 94107 Hide Map Icon
mail-icon

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.
1

PLUMB Registry for Metastatic <span class="highlight">Lobular</span> Breast Cancer

Improving Survival for Those With Metastatic <span class="highlight">Lobular</span> Breast Cancer Through Development of the Multi-center PLUMB Registry-a Prospective Study of <span class="highlight">LobUlar</span> Metastatic Breast Cancer

Purpose: To create a registry to study metastatic <span class="highlight">lobular</span> breast cancer, treatment patterns, and overall survival.

Who is this for?: People with stage IV (metastatic) <span class="highlight">lobular</span> breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples will be used to study the relationship between ctDNA and disease progression.</li> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small pieces of cancer cell DNA in the bloodstream.</li> <li class="seamTextUnorderedListItem">This trial will also develop an ongoing platform for evaluating new imaging tools, tumor markers, and participant recruitment for clinical trials.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05964504' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://clinicaltrials.ucsf.edu/trial/NCT05964504' target='_blank'>University of California, San Francisco: Trial Information Page</a> </li></ul>
1

PLUMB Registry for Metastatic <span class="highlight">Lobular</span> Breast Cancer

Improving Survival for Those With Metastatic <span class="highlight">Lobular</span> Breast Cancer Through Development of the Multi-center PLUMB Registry-a Prospective Study of <span class="highlight">LobUlar</span> Metastatic Breast Cancer
Icon

Nearest Location from 94107:
5 miles
University of California, San Francisco
San Francisco, CA

Icon

Visits:
Coincides with routine care

Icon

ClinicalTrials.gov: NCT05964504

Icon

Phase NA

2

PET/CT Scans with 68Ga-Ga DOTA-5G for Advanced <span class="highlight">Lobular</span> Breast Cancer

[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive <span class="highlight">Lobular</span> Breast Cancer (LBC)

Purpose: To study if PET/CT scans with 68Ga-Ga DOTA-5G, an experimental radioactive tracer, improve the ability to detect <span class="highlight">lobular</span> breast cancer.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) <span class="highlight">lobular</span> breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan with 68Ga-Ga DOTA-5G, by injection</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">68Ga-Ga DOTA-5G is an experimental tracer that can look for and attach to cancer cells during PET/CT scans.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07020806' target='_blank'>ClinicalTrials.gov</a> </li></ul>
2

PET/CT Scans with 68Ga-Ga DOTA-5G for Advanced <span class="highlight">Lobular</span> Breast Cancer

[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive <span class="highlight">Lobular</span> Breast Cancer (LBC)
Icon

Nearest Location from 94107:
74 miles
University of California Davis
Sacramento, CA

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT07020806

Icon

Phase I

3

PET/CT Scan for Detecting Metastasis in <span class="highlight">Lobular</span> Breast Cancer

A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer

Purpose: To determine whether PET/CT scans with piflufolastat F18 (PYLARIFY®) can be used to detect metastasis of breast cancer.

Who is this for?: People with metastatic (stage IV) <span class="highlight">lobular</span> breast cancer or stage I, stage II, or stage III <span class="highlight">lobular</span> breast cancer that is suspected to have spread. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Piflufolastat F18 (PYLARIFY®), by IV, 1 time</li> <li class="seamTextUnorderedListItem">PET/CT scan, 1 time</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Piflufolastat F18 (PYLARIFY®) is a tracer that is used to detect metastasis in people with prostate cancer. This trial will determine if it can also be used for breast cancer.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05394259' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/drugs-supplements/piflufolastat-f-18-intravenous-route/description/drg-20516701' target='_blank'>Mayo Clinic: Piflufolastat F18 (PYLARIFY®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/tests/pet-ct-scan' target='_blank'>Cancer Research UK: PET/CT Scan</a> </li></ul>
3

PET/CT Scan for Detecting Metastasis in <span class="highlight">Lobular</span> Breast Cancer

A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
Icon

Nearest Location from 94107:
1643 miles
MD Anderson Cancer Center
Houston, TX

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT05394259

Icon

Phase I

4

Biomarkers to Detect Resistance to Hormone Therapy for Advanced HR+, HER2- <span class="highlight">Lobular</span> Breast Cancer

Integrating Minimally Invasive Biomarkers of Estrogen Signaling to Detect Endocrine Therapy Resistance in Metastatic Invasive <span class="highlight">Lobular</span> Breast Cancer

Purpose: To identify possible biomarkers of response to hormone therapy for advanced <span class="highlight">lobular</span> breast cancer.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ or ER low and/or PR+ or PR low), HER2 negative (HER2-) <span class="highlight">lobular</span> breast cancer (LBC) who are planning to receive hormone therapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scans with 18F-FFNP, by IV, 2 times, at baseline and at 1 month</li> <li class="seamTextUnorderedListItem">Blood tests, 2 times, at baseline and at 1 month</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biomarkers are genes, molecules, or other features present in a person, including in a person’s tumor, that tell doctors something about a person’s health condition.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">The tracer used in this study is 18F-FFNP.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy. MRI scans study the blood vessels in the tumor. PET/CT scans study if the tumor cells are growing.</li> <li class="seamTextUnorderedListItem">The blood samples will be used to conduct DNA and circulating tumor cell (CTC) testing.</li> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTCs) are cancer cells from a tumor that circulate in the bloodstream.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06067503' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment' target='_blank'>National Cancer Institute: Biomarker Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/pet-scans' target='_blank'>Breastcancer.org: PET Scans</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/ct-scan' target='_blank'>Breastcancer.org: CT Scans</a> </li></ul>
4

Biomarkers to Detect Resistance to Hormone Therapy for Advanced HR+, HER2- <span class="highlight">Lobular</span> Breast Cancer

Integrating Minimally Invasive Biomarkers of Estrogen Signaling to Detect Endocrine Therapy Resistance in Metastatic Invasive <span class="highlight">Lobular</span> Breast Cancer
Icon

Nearest Location from 94107:
1678 miles
UW Carbone Cancer Center
Madison, WI

Icon

Visits:
2 visits within 1 month

Icon

ClinicalTrials.gov: NCT06067503

Icon

Phase II

5

Probiotic Supplement for Women With Breast Cancer

A Randomized, Double-blind, Placebo Controlled, Parallel Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer Patients

Purpose: To study how well a probiotic can change the mix of microorganisms (like bacteria and fungi) in the gut microbiome and breast tissue in people with breast cancer.

Who is this for?: Women with stage I or stage II or stage III or stage IV (invasive ductal carcinoma [IDC] or invasive <span class="highlight">lobular</span> carcinoma [ILC]) breast cancer. You must agree to avoid unpasteurized fermented foods and probiotics and to keep your usual diet and activity level before the study starts and while you are in the study. View full eligibility criteria

What's involved?


What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The gut microbiome is made up of bacteria, viruses, and other organisms that live in the digestive tract and help keep us healthy.</li> <li class="seamTextUnorderedListItem">A probiotic, called BIOHM, is a food supplement that is believed to balance bacteria and fungi in the body.</li> <li class="seamTextUnorderedListItem">This study is looking at whether taking BIOHM may help change the body’s microbiome in people with breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04362826' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/managing-life/diet-nutrition/dietary-supplements/known/probiotics' target='_blank'>Breastcancer.org: Probiotics and Breast Cancer</a> </li></ul>
5

Probiotic Supplement for Women With Breast Cancer

A Randomized, Double-blind, Placebo Controlled, Parallel Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer Patients
Icon

Nearest Location from 94107:
2172 miles
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Cleveland, OH

Icon

Visits:
At least 2 visits in 6 weeks

Icon

ClinicalTrials.gov: NCT04362826

Icon

Phase NA

6

Liquid Biopsy to Monitor Treatment Response for Women with Metastatic <span class="highlight">Lobular</span> ER+ Breast Cancer

LBC-Monitor: Liquid Biopsy Guided Tailoring of Therapy in Metastatic <span class="highlight">Lobular</span> Breast Cancer (mILC): a Pilot Study of Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA

Purpose: To study how circulating tumor DNA (ctDNA) changes over time to help monitor treatment response and make treatment decisions.

Who is this for?: Women with metastatic (stage IV) estrogen receptor positive (ER+) or ER low, HER2 negative (HER2-) <span class="highlight">lobular</span> breast cancer who have not yet received treatment for metastatic disease. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests, 4 times in 3 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lobular breast cancer can be difficult to see and monitor on scans.</li> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small pieces of cancer cell DNA in the bloodstream.</li> <li class="seamTextUnorderedListItem">A ctDNA test is sometimes called a liquid biopsy.</li> <li class="seamTextUnorderedListItem">ctDNA tests may improve the ability to monitor treatment response in <span class="highlight">lobular</span> breast cancer and identify changes in the tumor cells that may predict resistance to hormone therapy.</li> <li class="seamTextUnorderedListItem">This information may allow doctors to change treatments when it is most beneficial to patients.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06666439' target='_blank'>ClinicalTrials.gov</a> </li></ul>
6

Liquid Biopsy to Monitor Treatment Response for Women with Metastatic <span class="highlight">Lobular</span> ER+ Breast Cancer

LBC-Monitor: Liquid Biopsy Guided Tailoring of Therapy in Metastatic <span class="highlight">Lobular</span> Breast Cancer (mILC): a Pilot Study of Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA
Icon

Nearest Location from 94107:
2264 miles
Magee Women's Hospital of UPMC
Pittsburgh, PA

Icon

Visits:
4 visits in 3 months

Icon

ClinicalTrials.gov: NCT06666439

Icon

Phase NA

7

Epidiferphane Nutritional Supplement with Chemotherapy for Stage I-IV Breast Cancer

Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of epidiferphane, an experimental nutritional supplement, with chemotherapy.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning on receiving treatment with chemotherapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Epidiferphane, by mouth, daily for 3 months</li> <li class="seamTextUnorderedListItem">Physician's choice of chemotherapy: Docetaxel (Taxotere®), every 3 weeks; paclitaxel (Taxol®), weekly; or nab-paclitaxel (Abraxane®), weekly; 3 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Epidiferphane is an experimental nutritional supplement that may reduce chemotherapy symptoms.</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®), paclitaxel (Taxol®), and nab-paclitaxel (Abraxane®) are chemotherapy drugs.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with <span class="highlight">lobular</span> breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05074290' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/epidiferphane' target='_blank'>National Cancer Institute: Epidiferphane</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/chemotherapy' target='_blank'>Breastcancer.org: Chemotherapy</a> </li></ul>
7

Epidiferphane Nutritional Supplement with Chemotherapy for Stage I-IV Breast Cancer

Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients
Icon

Nearest Location from 94107:
2351 miles
University of Florida
Gainesville, FL

Icon

Visits:
1 visit every 1-3 weeks for 3 months

Icon

ClinicalTrials.gov: NCT05074290

Icon

Phase I-II

HELP GUIDE